trending Market Intelligence /marketintelligence/en/news-insights/trending/j0ryrixb1tkamkfsz84hpq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Admedus to raise about A$6M in placement

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Admedus to raise about A$6M in placement

Australia's Admedus Ltd. is raising about A$6 million in a placement of shares to investors.

The company is selling 20 million shares at 30 Australian cents per share under the placement. The company's directors are contributing 12% of the placement, subject to shareholder approval.

Admedus also invited its shareholders to participate in a share purchase plan for the opportunity to subscribe for up to A$15,000 of new shares at the placement price. The plan will be available to shareholders on record May 9 and have a registered address in Australia or New Zealand.

Admedus will use proceeds from the placement and share purchase plan to expand its strategic projects.

CCZ Statton Equities acted as the lead manager for the placement, which is expected to be completed May 16.

Admedus develops and sells healthcare devices. Among its products is CardioCel, which is used in the repair of congenital heart deformities and defects.